

Tele: 25683476

Central Organisation ECHS
Integrated HQ of MoD (Army)
Adjutant General's Branch
Thimayya Marg
Near Gopinath Circle
Delhi Cantt-110010

B/49762/AG/ECHS

28 Jun 2021

IHQ of MoD (Navy)/Dir ECHS (N)
Air HQ (DAV)/Coord
HQ Southern Command (A/ECHS)
HQ Eastern Command (A/ECHS)
HQ Western Command (A/ECHS)
HQ Central Command (A/ECHS)
HQ Northern Command (A/ECHS)
HQ South Western Command (A/ECHS) A.
HQ Andaman & Nicobar Command (A/ECHS)
All Regional Centres

**GUIDANCE FOR PRESCRIPTION OF COSTLY ONCOLOGY
DRUGS FOR ECHS PATIENTS**

1. PI ref MDTC, AH (R&R) letter No 1015/GC/MDTC/2021 dt 12 Jun 2021 (copt att).
2. Medical Oncology is a rapidly evolving specialty and research is producing newer and better molecules daily.
3. Dissemination of information on all these molecules is fast now a days due to the availability of various media. Doctors as well as patients are aware of the latest trends from the internet.
4. However it is also true that many of the early trends or promising data do not get converted to standard guidelines. Also as Indian patients are not significantly included in the trials, approval in India for these drugs takes a little longer.
5. Doctors from empanelled hospitals have been prescribing the latest molecules for ECHS patients based on publications in journals for FDA approval.
6. Therefore AH (R&R) have decided to streamline the usage of these costly and newer molecules so that the approval process becomes easier. Prescribing a drug not approved by DCGI in India for specific disease will not be in the best interests of the patient as well as our organization.
7. It is recommended that all newer and costly drugs be prescribed for only DCGI approved indications for ECHS empanelled patients.
8. In case of rare scenario where a patient has exhausted all approved molecules and is in good general condition he may be referred to AH (R&R)/ Comd Hosp/ Zonal Hosp (if Oncologist is available) for opinion on any specified newer therapies.

9. Also it is noted that many hospitals do not submit a proper summary of the case when submitting documents for approval. To bring about uniformity in this process we are attaching a one page short summary proforma is att herewith which is mandatory for approval of chemotherapy. The same format (duly filled by concerned Emp/Non Emp Hosp) has to be forwarded along with prior approval cases of cancer treatment also.

10. With effect from 15 Jul 2021 all approval will be based on this guidance. Patients who have already been approved for any therapy prior to this date will be treated as approved.

11. All RCs are requested to disseminate above guidelines to all ECHS PCs and Emp Hosp and advise them to strictly follow it.

12. For info and necessary action pl.



(Panchal Kalpeshkumar S)
Lt Col
Jt Dir (Med)
for Dir (Med)

Encls : As above.

Copy to :-

DGAFMS/DG-3A

DGMS (Army)/ DGMS – 5 (B)

DGMS (Air Force) (Med-7)

DGMS (Navy)/ Dir ECHS (Navy)

✓ HQ Cost Guard Veteran Cell
(Email –cgvcopers@indian cost guard.nic.in)

AMA ECHS, Embassy of India, Nepal

- for your info pl.


Internal

Ops & Coord, Claim Sec - for info pl.
Stats & Automation Sec - for uploading this letter on ECHS website.

1015/GC/MDTC/2021


12 Jun 2021

Director Medical
Central Organisation ECHS
ECHS Bhavan
Near Gopinath Circle
Thimmayya Road
Delhi Cantt, New Delhi-110010



Guidance for prescription of costly Oncology drugs for ECHS patients

1. Medical Oncology is a rapidly evolving specialty and research is producing newer and better molecules daily.
2. Dissemination of information on all these molecules is fast now a days due to the availability of various media. Doctors as well as patients are aware of the latest trends from the internet.
3. However it is also true that many of the early trends or promising data do not get converted to standard guidelines. Also as Indian patients are not significantly included in the trials, approval in India for these drugs takes a little longer.
4. Doctors from empanelled hospitals have been prescribing the latest molecules for ECHS patients based on publications in journals or FDA approval.
5. Hence at this hospital we have decided to stream line the usage of these costly and newer molecules so that the approval process becomes easier from both ends. Prescribing a drug not approved by DCGI in India for specific disease will not be in the best interests of the patient as well as our organization.
6. It is recommended that all newer and costly drugs be prescribed for only DCGI approved indications for ECHS empanelled patients.
7. In case of rare scenario where a patient has exhausted all approved molecules and is in good general condition he may be referred to this centre for opinion on any specified newer therapies.
8. Also it is noted that many hospitals do not submit a proper summary of the case when submitting documents for approval. To bring about uniformity in this process we are attaching a one page short summary performa which may be made mandatory for approval of chemotherapy (Attached as Appendix 'A').
9. It is requested that this guidance be disseminated to all empanelled hospitals, in Delhi/NCR so that the approval process becomes streamlined.
10. With effect from 30 June 2021 all approval from this centre will be based on this guidance. Patients who have already been approved for any therapy prior to this date will be continued till progression or as decided by treating physician.


(P Suresh)
Col
Sr Adv (Med) & Onco Med
Army Hospital (R&R)

Copy to
Director
Regional Centre 1 ECHS
ECHS Bhavan
Near Gopinath Circle
Thimmayya Road
Delhi Cantt, New Delhi- 110010

Summary Proforma for Approval of Chemotherapy for ECHS patientsNameAgeSex

Comorbidities:

Diagnosis:Stage T N MPerformance status:Special markers for any targeted therapy: (Attach reports)Surgery: - Yes/No (Short details)Radiotherapy: - Yes/No (Short details)Chemotherapy

Line of chemotherapy (1/2/3)	From	To	Total No of Cycle	Response

Present proposed plan:

DCGI approved – Yes/No

Justification : (Required only if the plan / drug being proposed is not as per the recommended indication by DCGI)Estimated cost: